Close Menu
Money MechanicsMoney Mechanics
    What's Hot

    Is Now the Time To Load Up on Bonds? Vanguard Thinks So

    February 5, 2026

    Mt. Logan to assume more prominent role in Everest’s capital mix as AUM surpasses $2.5bn: Williamson

    February 5, 2026

    Here’s the breakdown of U.S. borrowers

    February 5, 2026
    Facebook X (Twitter) Instagram
    Trending
    • Is Now the Time To Load Up on Bonds? Vanguard Thinks So
    • Mt. Logan to assume more prominent role in Everest’s capital mix as AUM surpasses $2.5bn: Williamson
    • Here’s the breakdown of U.S. borrowers
    • OpenAI launches new agentic coding model only minutes after Anthropic drops its own
    • Texas anti-ESG law declared unconstitutional by US judge – Oil & Gas 360
    • Silver Price Chaos Is Forcing the World’s Largest Jeweler To Shift Strategy
    • Your Monthly Cash Equities Volume Briefing
    • Wall Street Thinks Peloton Stock Can Recover. That’s Not Happening Today
    Facebook X (Twitter) Instagram
    Money MechanicsMoney Mechanics
    • Home
    • Markets
      • Stocks
      • Crypto
      • Bonds
      • Commodities
    • Economy
      • Fed & Rates
      • Housing & Jobs
      • Inflation
    • Earnings
      • Banks
      • Energy
      • Healthcare
      • IPOs
      • Tech
    • Investing
      • ETFs
      • Long-Term
      • Options
    • Finance
      • Budgeting
      • Credit & Debt
      • Real Estate
      • Retirement
      • Taxes
    • Opinion
    • Guides
    • Tools
    • Resources
    Money MechanicsMoney Mechanics
    Home»Guides & How-To»Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism
    Guides & How-To

    Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism

    Money MechanicsBy Money MechanicsSeptember 5, 2025No Comments2 Mins Read
    Facebook Twitter LinkedIn Telegram Pinterest Tumblr Reddit WhatsApp Email
    Tylenol Maker Kenvue’s Stock Slumps Following Report RFK Jr. Will Link It to Autism
    Share
    Facebook Twitter LinkedIn Pinterest Email



    Key Takeaways

    • Kenvue’s stock slumped Friday after The Wall Street Journal reported federal officials plan to link use of one of its products, Tylenol, with autism.
    • Kenvue said it has “continuously evaluated” Tylenol and believes there is no link between its active ingredient, acetaminophen, and autism.
    • A number of other over-the-counter drugs contain acetaminophen, but their manufacturers’ stocks haven’t taken the same hit as Kenvue.

    Shares of Tylenol-maker Kenvue (KVUE) plunged over 9% Friday following a report that federal health officials may link use of the painkiller during pregnancy to autism.

    Health Secretary Robert F. Kennedy Jr. plans to announce a report saying the use of Tylenol during pregnancy may be one of several causes of autism, The Wall Street Journal reported Friday afternoon, citing people familiar with the matter. A spokesperson for the Department of Health and Human Services told Investopedia that it is “using gold-standard science to get to the bottom of America’s unprecedented rise in autism rates,” and that until the final report is released, any claims about its contents should be treated as speculation.

    Kenvue said the active ingredient in Tylenol, acetaminophen, was studied for more than a decade by the U.S. Federal Drug Administration, which concluded research hasn’t supported a causal link between acetaminophen and autism.

    “Nothing is more important to us than the health and safety of the people who use our products,” Kenvue said in a statement. “We have continuously evaluated the science and continue to believe there is no causal link between acetaminophen use during pregnancy and autism.”

    RFK Jr., who has pledged to identify the cause of autism, has also previously voiced concerns about vaccines and other medical treatments deemed safe by the medical establishment.

    A number of other painkillers and congestion relievers available without prescriptions contain acetaminophen, including Benadryl, Sudafed, DayQuil, Excedrin, NyQuil, Robitussin and Vicks, according to BeMedWise, a patient safety and education group. Benadryl and Sudafed are sold by Kenvue in the U.S., according to Kenvue’s website.

    Shares of manufacturers for many of the other products with acetaminophen haven’t taken the same hit as Kenvue. Haleon (HLN), which sells Excedrin and Robitussin, was recently off by less than 1%, while shares of Procter & Gamble (PG), which sells Vicks, DayQuil and NyQuil, finished Friday’s session up less than 1%.



    Source link

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleKiplinger News Quiz, September 5, 2025
    Next Article Frontier GoWild! Pass Review 2025: Is the $299 All-You-Can-Fly Deal Worth It?
    Money Mechanics
    • Website

    Related Posts

    Google Says Spending Could Double This Year Amid Its AI Push. Investors Don’t Seem Excited

    February 5, 2026

    4 Estate Planning Documents Every High-Net-Worth Family Needs

    February 5, 2026

    AI Has Eliminated Entry-Level Jobs but These Graduate Careers Are Still Flourishing

    February 5, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Is Now the Time To Load Up on Bonds? Vanguard Thinks So

    February 5, 2026

    Mt. Logan to assume more prominent role in Everest’s capital mix as AUM surpasses $2.5bn: Williamson

    February 5, 2026

    Here’s the breakdown of U.S. borrowers

    February 5, 2026

    OpenAI launches new agentic coding model only minutes after Anthropic drops its own

    February 5, 2026

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading

    At Money Mechanics, we believe money shouldn’t be confusing. It should be empowering. Whether you’re buried in debt, cautious about investing, or simply overwhelmed by financial jargon—we’re here to guide you every step of the way.

    Facebook X (Twitter) Instagram Pinterest YouTube
    Links
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    • Terms and Conditions
    Resources
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To
    Get Informed

    Subscribe to Updates

    Please enable JavaScript in your browser to complete this form.
    Loading
    Copyright© 2025 TheMoneyMechanics All Rights Reserved.
    • Breaking News
    • Economy & Policy
    • Finance Tools
    • Fintech & Apps
    • Guides & How-To

    Type above and press Enter to search. Press Esc to cancel.